Sirolimus-eluting iron bioresorbable scaffold in coronary artery disease: two-year results of IRONMAN-II randomised controlled trial
Reported from TCT 2025
Alex Sticchi interviews Lei Song on the IRONMAN II trial he presented at TCT 2025, in San Francisco.
At 2 years, sirolimus-eluting bioresorbable scaffolds were non-inferior to DES, with similar clinical outcomes; longer-term follow-up will determine whether late benefits emerge after complete scaffold resorption.
Authors
No comments yet!